Viewing Study NCT01295632

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:46 PM
Ignite Modification Date: 2026-03-26 @ 5:47 PM
Study NCT ID: NCT01295632
Status: COMPLETED
Last Update Posted: 2015-08-27
First Post: 2011-02-09
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Sponsor: Merck Sharp & Dohme LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Recurrent glioblastoma multiforme View
None Hormone resistant prostate cancer View
None Relapsed ovarian carcinoma View
None Refractory ovarian carcinoma View
None Refractory breast cancer View
None Relapsed breast cancer View